As previously discussed on this board, this is a tough indication in which to show a clinical benefit relative to placebo.
Episodic migraine is (was) ABP-450’s lead indication. The lead indication had previously been cervical dystonia, but AEON backed off from CD due, presumably, to RVNC’s stellar dataset in that indication.
AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau. Please see #msg-172274907 for related info.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.